GlassScriptPhysician profile
Miguel P Rivera
NPI 1104840404
$6,953.23
in general payments reported to CMS, 2019-2025
52 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $848 · 2021: $1,178 · 2022: $480 · 2023: $562 · 2024: $1,400 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $603.12 | 2019-2025 | Xyosted |
| Novo Nordisk INC | $537.65 | 2019-2025 | Sogroya, Ozempic, Rybelsus |
| Beta Bionics, INC. | $485.66 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $484.99 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $459.14 | 2019-2024 | |
| Abbvie INC. | $403.30 | 2020-2025 | Ubrelvy |
| Xeris Pharmaceuticals, INC. | $376.38 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $363.04 | 2020-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.03 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $236.73 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $203.99 | 2021-2025 | |
| Amarin Pharma, INC. | $164.94 | 2019-2021 | |
| Abbott Laboratories | $163.54 | 2019-2023 | Freestyle Libre 3 |
| Clarus Therapeutics INC. | $160.91 | 2021 | |
| Alexion Pharmaceuticals, INC. | $139.90 | 2019-2025 | Strensiq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.